Also trades as: ENLV.TA (TLV) · $vol 0M
ENLV NASDAQ
Enlivex Therapeutics Ltd.
1W: -22.7%
1M: -73.2%
3M: -92.8%
YTD: -98.6%
1Y: -99.0%
3Y: -99.3%
5Y: -99.9%
$2.75
+0.15 (+5.83%)
Weekly Expected Move ±14.7%
$0
$0
$0
$0
$0
Credit Risk of going bust: higher than 96% of companies Debt: 86.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.11 (down 34%), Enlivex Therapeutics Ltd. would be worth roughly what it owes.
Total debt $17.2M against a stock market value of $2.7M.
Distance to default 0.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $16.9M (short-term plus half of long-term), stock volatility 108.5%; Altman Z'' 11.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $17.2M against a stock market value of $2.7M.
Distance to default 0.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $16.9M (short-term plus half of long-term), stock volatility 108.5%; Altman Z'' 11.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.7M
52W Range0.1607-27.15
Volume402,798
Avg Volume784,491
Beta1.41
Dividend—
Analyst Ratings
Company Info
CEOOren Hershkovitz
Employees34
SectorHealthcare
IndustryBiotechnology
IPO Date2014-07-31
Websiteenlivex.com
14 Einstein Street
Ness Ziona, TA 7403618
IL
Ness Ziona, TA 7403618
IL
972 8 662 3301
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hershkovitz Oren | 0 | — | 2026-03-18 | |
| Shlosberger Shachar | 0 | — | 2026-03-18 | |
| Hart Gili | 0 | — | 2026-03-18 | |
| Hart Gili | 3,382 | $5.34 | 2026-03-18 | |
| NOVIK SHAI A | 0 | — | 2026-03-18 |